netFormulary NHS
Pan Mersey
Area Prescribing Committee
 Formulary Chapter 2: Cardiovascular system - Full Section

Coronavirus guidance

Guidance to support primary care prescribers and pharmacists is available from the MLCSU Coronavirus guidance resource page. Links are provided to national resources and regional documents produced by MLCSU, RDTC, and SPS for use by Pan Mersey APC, LSCMMG, and GMMMG.

The list of resources will be updated as new material becomes available so please check back regularly for updates.

The Pan Mersey APC supports the use of COVID-specific guidance issued by NICE, and NHS England and NHS Improvement. During the COVID pandemic this will supersede any APC advice.

Cardiovascular system

Review date: March 2022

Non-formulary drugs: Any drug or formulation not listed in the formulary is deemed to be non-formulary.

Off-label use: Drugs are included in the formulary for their licensed indications – where inclusion of off-label use is considered to be included in the formulary this is specifically stated in the formulary entry for the drug N.B. also see Paediatrics note below.

Paediatrics: Drugs are included in the formulary for paediatric use for their BNF for Children recommended indications (indicated by symbol View childrens BNF) which may be off-label, unless otherwise stated. All drugs are deemed to have the same RAG status as they have for adults unless stated otherwise.

NHS England Specialised Commissioning
Drugs carrying the NHS England logo are commissioned by them. Links to key documents, national programmes of care, and clinical reference groups are found below.

NHSE NHS England Specialised Commissioning: Key documents

NHSE NHS England Specialised Commissioning: National programmes of care and clinical reference groups

 Useful Links

02.01 Positive inotropic drugs
02.01.01 Cardiac glycosides
Digoxin-specific antibody
02.01.02 Phosphodiesterase type-3 inhibitors
02.02 Diuretics
02.02.01 Thiazides and related diuretics
02.02.02 Loop diuretics
02.02.03 Potassium-sparing diuretics and aldosterone antagonists
Aldosterone antagonists
02.02.04 Potassium-sparing diuretics with other diuretics
02.02.05 Osmotic diuretics
02.02.06 Mercurial diuretics
02.02.07 Carbonic anhydrase inhibitors
02.02.08 Diuretics with potassium
02.03 Anti-arrhythmic drugs
02.03.01 Management of arrhythmias
02.03.02 Drugs for arrhythmias
Supraventricular arrhythmias
Supraventricular and ventricular arrhythmias
Ventricular arrhythmias
02.04 Beta-adrenoceptor blocking drugs
02.05 Drugs affecting the renin-angiotensin system and some other antihypertensive drugs
02.05.01 Vasodilator antihypertensive drugs
02.05.02 Centrally acting antihypertensive drugs
02.05.03 Adrenergic neurone blocking drugs
02.05.04 Alpha-adrenoceptor blocking drugs
02.05.05 Drugs affecting the renin-angiotensin system
Heart Failure Angiotensin-converting enzyme inhibitors (ACE inhibitors) Angiotensin-II receptor antagonists Renin inhibitors
02.06 Nitrates, calcium-channel blockers, and potassium-channel activators
02.06.01 Nitrates
02.06.02 Calcium-channel blockers
02.06.03 Other anitanginal drugs
02.06.04 Peripheral vasodilators and related drugs
Other preparations used in peripheral vascular disease
02.07 Sympathomimetics
02.07.01 Inotropic sympathomimetics
02.07.02 Vasoconstrictor sympathomimetics
02.07.03 Cardiopulmonary resuscitation
02.08 Anticoagulants and protamine
02.08.01 Parenteral anticoagulants
Low molecular weight heparins
Heparin flushes
02.08.02 Oral anticoagulants
02.08.03 Protamine sulphate
02.09 Antiplatelet drugs
02.10 Stable angina, acute coronary syndromes, and fibrinolysis
02.10.01 Management of stable angina and acute coronary syndromes
02.10.02 Fibrinolytic drugs
02.11 Antifibrinolytic drugs and haemostatics
Blood-related products
02.12 Lipid-regulating drugs
Bile acid sequestrants
Nicotinic acid group
Omega-3 fatty acid compounds
02.13 Local sclerosants